You just read:

Daiichi Sankyo Advances [Fam-] Trastuzumab Deruxtecan (DS-8201) in Japan with Regulatory Submission in HER2 Positive Metastatic Breast Cancer

News provided by

Daiichi Sankyo Company, Limited

Sep 09, 2019, 08:00 ET